Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.92) by 10.87 percent. This is a 18.84 percent decrease over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $22.10 million which beat the analyst consensus estimate of $10.15 million by 117.63 percent. This is a 114.83 percent increase over sales of $10.29 million the same period last year.